Propanc Biopharma Says Preclinical PRP Data In Pancreatic Cancer Models Showed Greater Than 90% Mean Tumor Growth Inhibition, More Than 2.5-Fold Median Survival Extension

Crude Oil Moves Higher; Dollar General Shares Gain After Upbeat Q2 Earnings

U.S. stocks traded higher, Dow up 0.20%, NASDAQ up 1.05%, S&P 500 up 0.47%. Tech shares jumped 2.4% while consumer staples fell 1%. Dollar General gained 5% on strong earnings. Propanc Biopharma soared 157%. Okta and Veeva Systems also rose. Build-A-Bear Workshop and Healthequity fell on earnings. European and Asian markets closed mostly lower.

Revolution Medicines’ Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma’s Breakthrough Survival Results

Propanc Biopharma reports strong preclinical data from pancreatic cancer drug, PRP, showing over 90% tumor inhibition and extended survival.

Nasdaq Surges 200 Points; Nvidia Posts Upbeat Q2 Results

US stocks traded higher with Nasdaq up 200 points. Dow down 0.01%, Nasdaq up 0.77%, and S&P 500 up 0.27%. Tech shares rose 2.2% while consumer staples fell 1.1%. Nvidia reported strong earnings. Propanc Biopharma up 211%, VolitionRX up 86%, Mint Incorporation up 74%, Alpha Modus down 25%, Change Agents down 29%, and Xiao-I down 21%.

Propanc Biopharma shares are trading higher after the company announced preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma.